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OBJECTIVES The purpose of this study was to determine the clinical and angiographic correlates and
outcomes of patients with suboptimal coronary flow after primary percutaneous coronary
interventions (PCI).
BACKGROUND The clinical and angiographic correlates and outcomes of Thrombolysis in Myocardial
Infarction (TIMI) 2 flow in patients treated with primary PCI are not known.
METHODS We evaluated 3,362 patients with ST elevation myocardial infarction enrolled in various
Primary Angioplasty in Myocardial Infarction trials, who underwent primary PCI.
RESULTS Post-procedural final TIMI 2 flow occurred in 232 (6.9%) patients. Multivariate analysis
identified age 70 years (odds ratio [OR], 1.6; 95% confidence interval [CI], 1.1 to 2.2),
diabetes (OR 1.9; 95% CI, 1.3 to 2.7), symptom onset to emergency room presentation
(OR 1.1; 95% CI, 1.1 to 1.2); initial TIMI 1 flow (OR 3.2; 95% CI, 1.9 to 5.5), and left
ventricular ejection fraction 50% (OR 1.7; 95% CI, 1.2 to 2.4) as independent correlates of
final TIMI 2 flow. In-hospital (composite of reinfarction, ischemic target vessel revascu-
larization, or death, as well as these events individually) and one-year (reinfarction and/or
death) events occurred more frequently in patients with TIMI 2 flow. The Cox
proportional hazards model identified TIMI 2 flow to be independently associated with
one-year mortality (hazard ratio 3.8, 95% CI, 2.5 to 5.7).
CONCLUSIONS Final TIMI 2 flow, although uncommon after primary PCI, was strongly associated with
hospital and one-year adverse events. The clustering of final TIMI 2 flow in high-risk
groups may partially explain the poor prognosis of these patients. Awareness of these risk
factors may be useful to clinicians to triage and treat patients undergoing primary
PCI. (J Am Coll Cardiol 2003;42:1739–46) © 2003 by the American College of
Cardiology Foundation
Reperfusion therapy is the cornerstone of the treatment of
patients with acute ST elevation myocardial infarction
(STEMI) (1). Many randomized clinical trials have shown
that primary percutaneous coronary intervention (PCI) is
superior to thrombolytic therapy in the treatment of patients
with STEMI (2–5). Nevertheless, the occurrence of
Thrombolysis in Myocardial Infarction (TIMI) 2 flow
remains the “Achilles heel” of primary PCI occurring in 2%
to 37% of patients (2–13), even in the era of the routine use
of stents and newer antithrombotic and antiplatelet agents,
strategies shown to improve the outcomes of patients
undergoing primary PCI (14–16). Furthermore, TIMI 2
flow has been shown to be associated with increased
incidence of major in-hospital adverse events in these
patients (10–12). Despite this, the clinical correlates of
TIMI 2 flow in patients undergoing primary PCI have
not been well characterized. Additionally, the in-hospital
and long-term outcomes have not been studied in a large
group of patients undergoing primary PCI. The purpose of
our study was to objectively characterize contemporary
clinical and angiographic variables associated with the risk
of TIMI 2 flow and the in-hospital and long-term
outcomes associated with it in a large cohort of patients
undergoing primary PCI.
METHODS
Patient population. The Primary Angioplasty in Myocar-
dial Infarction (PAMI) studies prospectively enrolled pa-
tients with STEMI into seven clinical trials (PAMI-1,
PAMI-2, PAMI Stent Pilot, Stent PAMI, Local PAMI,
Air PAMI, and PAMI–No Surgery on Site) (2,6,17–23).
Two of these trials (6,18) also enrolled patients into con-
comitant registries. The rationale, methodology, and the
results of the individual PAMI studies have been previously
published (2,6,17–23). Patients were included in these
investigations if they were 18 years of age with STEMI
presenting within 12 h of their symptom onset. Acute
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STEMI was defined by the following criteria: ST elevation
of at least 1 mm in 2 contiguous leads or presumed new
left bundle-branch block on the presenting 12-lead electro-
cardiogram. Patients were excluded from these trials if they
had contraindications to reperfusion (2), had received
thrombolytic therapy for index STEMI, had renal failure,
cardiogenic shock, or life expectancy less than one year; also
excluded were those with child-bearing potential (unless
the result of a recent pregnancy test was negative), or those
with known contraindications to aspirin, heparin, or ticlo-
pidine in later PAMI trials (6,19–23). Furthermore, pa-
tients randomized to the thrombolytic arm (PAMI-1 and
Air-PAMI) or those in whom primary PCI was not
attempted (defined as no attempt to pass a guide wire) were
also excluded from this analysis. Informed consent was
obtained from all patients by the study investigators or
coordinators at the respective institutions. For the purpose
of this study, we pooled the clinical, demographic, angio-
graphic, and in-hospital clinical events and outcomes data
on 3,362 patients enrolled in these trials who underwent
primary PCI.
Data collection and angiographic analyses. Research
nurses or a coordinator at each site collected data prospec-
tively on prespecified data elements on a case report form in
all trials. These data included baseline demographics, med-
ical history, medications, procedures, complications, and
clinical events. Follow-up was obtained at one year by
means of self-administered questionnaire, by telephone
interview or follow-up visit to the physician. Completed
case report forms were sent to the PAMI coordinating site
at Beaumont Hospital, Royal Oak, Michigan, where the
data were entered into an Access data base. Independent
data monitoring was performed through onsite visit of the
participating sites to verify records of all patients. The
cineangiograms obtained at the time of index intervention
were analyzed at the core laboratory site, which assessed
coronary anatomy, TIMI flow grades, percent diameter
stenosis, left ventricular ejection fraction (LVEF), and
angiographic outcomes of the intervention.
Definitions, comparison groups, and study end points.
Suboptimal coronary flow was defined as final TIMI 2
flow and normal flow as TIMI 3 flow in the infarct-related
artery. Reinfarction was defined as recurrent clinical symp-
toms or development of new electrocardiographic changes
accompanied by new elevation of creatine kinase and crea-
tine kinase MB enzyme levels. Ischemia-driven target vessel
revascularization was defined as PCI or coronary artery
bypass surgery of the index infarct-related artery prompted
by symptoms or objective evidence of ischemia. Sustained
hypotension was defined as systolic blood pressure80 mm
Hg unresponsive to intravenous fluids, requiring vasopres-
sors for1 h or intraaortic balloon pump. For this study, we
compared the baseline clinical, demographic, angiographic,
and in-hospital adverse events of patients with a final TIMI
2 (suboptimal flow) and those with TIMI 3 flow (normal
flow). The principal outcomes of interest for the current
study included the differences in the hospital and one-year
mortality, and hospital and one-year incidence of major
adverse cardiovascular events (MACE, defined as death, or
reinfarction, or ischemia-driven target vessel revasculariza-
tion) between the two comparison groups.
Statistical analysis. Summary statistics are presented as
frequencies and percentages or as medians as appropriate.
Comparisons between groups (TIMI 2 vs. TIMI 3 flow)
were made using the two-tailed Wilcoxon rank sum test for
continuous variables and the chi-square or Fisher exact test
(when expected frequency count in the cell 5) for cate-
gorical variables as appropriate. In all cases, missing data
were not defaulted to negative and denominators reflect
cases reported. Stepdown multivariable logistic regression
was constructed to identify clinical predictors of TIMI 2
flow using variables showing marginal association with it on
univariate testing (p  0.10). Variables were reviewed for
clinical significance before testing. Variables included in the
first step of the model development included age70 years,
gender, time of symptom onset to arrival in the emergency
room, medical history (diabetes, hypertension, previous
coronary artery bypass surgery, and smoking), presenting
features (pulse 100 beats/min, systolic blood pressure
100 mm Hg, and Killip class 1), concomitant treat-
ments (stents), and angiographic findings (left anterior
descending as infarct-related artery [vs. other coronary
arteries], initial TIMI flow, and percent stenosis of the
infarct-related artery and LVEF 50%). Only variables
with a significant (p 0.05) association with TIMI2 flow
were included in the final regression models. Adjusted odds
ratios and accompanying 95% confidence intervals (CIs)
were computed to determine the effect of each variable in
the final model on the risk of TIMI 2 flow. Diagnostic
routines (the Hosmer-Lemeshow test for lack of fit and
likelihood ratio test) were used for the final model selection.
The c-statistic was calculated to evaluate model discrimina-
tion. Finally, to determine the impact of TIMI 2 flow on
one-year mortality, we used the Cox proportional hazards
model to adjust for baseline differences in clinical charac-
teristics between the two groups. Hazard ratio and 95% CI
were constructed to provide estimate of risk posed by TIMI
2 flow on long-term (one-year) mortality. SAS software
(version 8.0, SAS Institute, Cary, North Carolina) was used
for all analyses.
Abbreviations and Acronyms
CI  confidence interval
LVEF  left ventricular ejection fraction
MACE  major adverse cardiovascular events
OR  odds ratio
PAMI  Primary Angioplasty in Myocardial Infarction
PCI  percutaneous coronary intervention
STEMI  ST elevation myocardial infarction
TIMI  Thrombolysis In Myocardial Infarction
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RESULTS
Clinical and angiographic characteristics of patients with
and without final TIMI<2 flow (Tables 1 and 2). Of the
3,362 patients with STEMI undergoing primary PCI in the
study, 232 (6.9%) had TIMI 2 flow after primary PCI.
The number of patients with TIMI 0, 1, and 2 flows were
45 patients (1.3%), 25 patients (0.7%), and 162 patients
(4.8%), respectively. Compared with the cohort with TIMI
3 flow, those with TIMI 2 flow were more likely to be 70
years or older, diabetic, hypertensive, with a history of
previous coronary artery bypass surgery, but less likely to
have ever smoked. There was a significant delay in the time
to presentation to the emergency room after symptom onset
in the group with TIMI 2 flow. Similarly, presentation
with adverse hemodynamics such as heart rate 100 beats/
min, blood pressure 100 mm Hg, and Killip class 1 was
more common in patients with TIMI 2 flow.
Angiographic characteristics also differed between the
two groups. Thus, patients with TIMI 2 flow were more
likely to have initial TIMI flow 1, higher initial percent
stenosis of infarct artery, left anterior descending as infarct-
related artery, and LVEF 50%. The post-procedural final
percent stenosis, presence of thrombus, and dissection of the
infarct artery were also higher in patients with TIMI 2
final flow. Intracoronary arteriolar vasodilators (nitroprus-
side, nitroglycerin, verapamil, adenosine) were used in all
patients with transient or final TIMI2 flow. Glycoprotein
IIb/IIIa receptor antagonist and intracoronary thrombolysis
were used more frequently in patients with TIMI 2 flow.
In contrast, intracoronary stents were used less frequently in
patients with TIMI 2 flow.
Complications in catheterization laboratory, in-hospital
and at one-year follow-up in patients with and without
final TIMI<2 flow (Tables 2 and 3). Patients with TIMI
2 were more likely to have experienced an adverse event
during the procedure. Thus, the incidence of sustained
hypotension, requirement for endotracheal intubation or
cardio-pulmonary resuscitation, and death was more com-
mon in this group of patients during primary PCI. These
increased complications in the catheterization laboratory
were further reflected in the higher rates of virtually all
adverse events seen during hospital stay in patients with
TIMI 2 flow, resulting in longer length of stay in these
patients (Table 3).
Table 1. Baseline Characteristics of Study Patients
TIMI Flow  3
(n  3,130)
TIMI Flow <2
(n  232)
p Valuen (%)
Mean age (SD), yrs 61 (12) 65 (12)  0.0001
Age 70 yrs 806 (26.0) 84 (36.0) 0.0005
Females 828 (26.0) 63 (27.0) 0.82
Mean BMI (SD), [median], kg/m2 27.6 (4.8) [26.8] 27.0 (4.5) [26.6] 0.18
Onset of symptom to ER, mean (SD) [median], min 152 (144) [105] 201 (237) [120] 0.0082
Onset of symptom to balloon, mean (SD) [median], min 283 (176) [230] 317 (194) [250] 0.0059
ER to balloon, mean (SD) [median], min 143 (161) [113] 145 (119) [120] 0.27
Past medical history
Angina 381 (17.0) 29 (16.0) 0.62
Myocardial infarction 431 (14.0) 35 (15.0) 0.59
Congestive heart failure 67 (2.2) 7 (3.1) 0.37
Diabetes 482 (15.0) 56 (24.0) 0.0005
Hypertension 1,395 (45.0) 118 (52.0) 0.046
Stroke or transient ischemic attack 155 (5.0) 17 (7.5) 0.099
Hyperlipidemia 913 (40.0) 62 (36.0) 0.33
Peripheral vascular disease 178 (5.8) 16 (7.3) 0.38
Current tobacco smoking 1,310 (42.0) 82 (36.0) 0.070
Ever smoked 1,968 (66.0) 132 (59.0) 0.032
PCI 302 (9.7) 16 (7.0) 0.17
CABG 111 (3.9) 15 (6.9) 0.033
Family history of CAD 829 (36.0) 62 (34.0) 0.63
Presentation
Pulse mean (SD), beats/min 87 (21) 92 (20) 0.0009
Pulse 100 beats/min 588 (21.0) 64 (29.0) 0.0035
Systolic blood pressure, mean (SD), mm Hg 111 (26) 108 (26) 0.032
Systolic blood pressure 100 mm Hg 860 (31.0) 82 (38.0) 0.047
Killip class 1 400 (12.9) 39 (17.3) 0.059
Medications before or during PCI
Aspirin 2,323 (94.0) 177 (97.0) 0.12
Ticlopidine 1,126 (77.0) 100 (80.0) 0.45
Beta-blockers 878 (40.0) 66 (39.0) 0.69
BMI  body mass index; CABG  coronary artery bypass grafting; CAD  coronary artery disease; ER  emergency room;
PCI  percutaneous coronary intervention; TIMI  Thrombolysis In Myocardial Infarction.
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The primary outcomes of interest for the PAMI studies,
that is, in-hospital and one-year MACE, occurred more
frequently in patients with TIMI 2 flow. The occurrence
of death and reinfarction were also significantly higher in
TIMI 2 flow during hospitalization and at one-year
follow-up. The Cox proportional hazards model identified
TIMI 2 flow as an independent predictor of one-year
mortality (hazard ratio 3.8, 95% CI 2.5 to 5.6, p  0.0001)
(Fig. 1). In-hospital mortality and one-year mortality and
MACE increased in patients with decreasing grades of
TIMI flow (p for trend 0.0001 for all three outcomes,
Fig. 2).
Clinical factors related to TIMI <2 flow (Table 4).
Stepdown logistic regression analysis identified age 70
years, diabetes, time of symptom onset to emergency room
arrival, initial TIMI 1 flow, and LVEF 50% as inde-
pendent correlates of TIMI 2 flow (Table 4). The area
under the receiver-operating curve for the model was 0.68.
The Hosmer-Lemeshow statistic was not significant, indi-
cating little deviation from perfect fit (chi-square 11.4,
degrees of freedom 8, p  0.18).
DISCUSSION
Findings of the present study. Failure to achieve normal
flow is increasingly recognized as primary PCI is becoming
a widely popular mode of reperfusion for patients with
STEMI at many centers. The emergence of contrast echo-
cardiography has allowed physicians to focus not only on
epicardial coronary flow but also on microvascular perfusion
(11). Our investigation provides a valuable insight into the
incidence, clinical correlates, risk factors, and in-hospital
and one-year outcomes of final TIMI 2 flow in a large
cohort of STEMI patients undergoing primary PCI. The
incidence of TIMI2 flow is not insignificant, occurring in
1 of 14 patients undergoing primary PCI. Although the
incidence of TIMI 2 flow in our study is lower than that
observed in studies that used contrast echocardiography
Table 2. Angiographic Data and Cath-Lab Complications of Study Patients
TIMI Flow  3
(n  3,130)
TIMI Flow <2
(n  232)
p Valuen (%)
Angiographic data—initial
Infarct-related artery
Left main 19 (0.6) 3 (1.3)
Left anterior descending 1,255 (40.7) 106 (46.9) 0.065
Left circumflex 444 (14.4) 26 (11.5) 0.23
Right coronary 1,341 (43.4) 86 (38.1) 0.11
Saphenous vein graft 28 (0.9) 5 (2.2)
Initial TIMI flow grade  0.0001
0 1,996 (64.0) 182 (78.5)
1 341 (10.9) 27 (11.6)
2 496 (15.9) 22 (9.5)
3 286 (9.2) 1 (0.4)
Initial patency (TIMI flow 2 or 3) 782 (25.0) 23 (10.0)  0.0001
Initial percent stenosis, mean (SD) [median] 98 (5) [100] 99 (7) [100]  0.0001
LVEF, mean (SD) 49 (12) 45 (12)  0.0001
LVEF 50% 1,303 (48.0) 118 (64.0)  0.0001
Medications, intra-aortic balloon pump and stent use
during the procedure
Glycoprotein IIb/IIIa inhibitors 269 (9.6) 25 (14.9) 0.025
Thrombolytics 139 (5.1) 23 (15.5)  0.0001
Stents 1,174 (38.0) 69 (30.0) 0.018
Intra-aortic balloon pump 32 (7.0) 3 (13) 0.23
Initial activated clotting time, mean (SD) 246 (161) 260 (197) 0.78
Angiographic data post procedure
Post-procedure percent stenosis, mean (SD)
[median]
13 (13) [10] 40 (37) [30]  0.0001
Final stenosis 50% 12 (0.4) 62 (28%)  0.0001
Final thrombus 231 (8.5) 63 (39.9)  0.0001
Final dissection 415 (15.0) 41 (26) 0.0004
Cath-lab complications 396 (22.0) 43 (40.0)  0.0001
Bradyarrhythmias 297 (25.0) 26 (31.0) 0.19
Ventricular arrhythmias 130 (12.0) 6 (8.0) 0.27
Cardiopulmonary resuscitation 15 (0.8) 6 (4.8) 0.0012
Endotracheal intubation 14 (0.7) 7 (5.6)  0.0001
Hypotension 132 (7.5) 22 (19.0)  0.0001
Death 2 (0.1) 2 (1.7) 0.02
Cath-lab  cardiac catheterization laboratory; LVEF  left ventricular ejection fraction; TIMI  Thrombolysis In Myocardial
Infarction.
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along with coronary angiography (10,11), it compares fa-
vorably with that seen in most large-scale trials comparing
the efficacy of primary PCI with thrombolysis or those
comparing primary angioplasty with primary stenting (2–
9,15–23). Furthermore, we found that the occurrence of
TIMI 2 flow is not a benign event: it is associated with
increased risk of complications not only in the cardiac
catheterization laboratory and in-hospital but also at long-
term follow-up. In contrast to patients treated with throm-
bolytic therapy, where rescue angioplasty in selected patients
who fail thrombolysis may have a potential to improve
outcomes, there are no good proven strategies to improve
final TIMI 2 flow after primary PCI. As a result, the
mortality in patients with TIMI 0, 1, and 2 flow in acute
myocardial infarction patients treated with primary PCI
patients is significantly greater than that observed in pa-
tients with similar grades of TIMI flow after thrombolysis
(24). Not surprisingly, because of the higher complications
in patients with TIMI 2 flow, the length of stay and
resource utilization are also increased in these groups of
patients. Thus, our findings underscore the importance of
preventing the development of TIMI 2 flow as the
optimal strategy to improve outcomes and decrease resource
utilization in patients undergoing primary PCI, as once
no-reflow occurs the outcomes are relatively dismal.
Clinical and angiographic factors associated with risk of
TIMI<2 flow in patients undergoing primary PCI. Few
previous studies involving a small number of patients have
evaluated predictors of TIMI 2 in patients with acute
STEMI undergoing primary PCI (25–27). These studies
have identified the absence of preinfarction angina, higher
Killip class at presentation, number of Q waves on present-
ing electrocardiogram, TIMI 0 flow at initial angiography,
anterior myocardial infarction, hyperglycemia, wall motion
score on echocardiography, and intravascular ultrasound
findings (abnormal lipid pool-like image and lesion elastic
membrane cross-sectional area) as predictors of TIMI 2
Table 3. In-Hospital Complications and Long-Term Outcomes
TIMI Flow  3
(n  3,130)
TIMI Flow <2
(n  232)
p Valuen (%)
In-hospital complications
Bradyarrhythmias 87 (2.8) 17 (7.3) 0.0001
Ventricular arrhythmias 117 (3.7) 14 (6.0) 0.081
Pulmonary edema 125 (4.5) 21 (13.0)  0.0001
Sustained hypotension 139 (5.3) 29 (18.0)  0.0001
Cardiopulmonary resuscitation 26 (0.9) 10 (4.5)  0.0001
Intraaortic balloon pump 50 (3.6) 13 (19)  0.0001
Ventricular septal rupture or severe mitral regurgitation 1 (0.03) 4 (1.7)  0.0001
Gastrointestinal bleeding 66 (2.6) 12 (6.5) 0.0028
Need for dialysis 11 (0.4) 2 (1.4) 0.15
Length of stay, mean (SD), days 6.4 (5.5) 8.1 (6.6)  0.0001
In-hospital outcomes
Reinfarction 53 (1.7) 8 (3.5) 0.068
Ischemic TVR 96 (3.2) 10 (4.5) 0.31
Death 65 (2.1) 34 (15.0)  0.0001
MACE 175 (5.6) 47 (20.0)  0.0001
Disabling stroke 8 (0.3) 1 (0.4) 0.48
MACE or disabling stroke 181 (6.1) 47 (21.0)  0.0001
One-year outcomes
Reinfarction 111 (4.4) 17 (9.3) 0.0028
Ischemic TVR 352 (15.0) 23 (13.0) 0.65
Death 133 (5.1) 47 (23.0)  0.0001
MACE 538 (20.0) 78 (37.0)  0.0001
Disabling stroke 16 (1.0) 2 (1.5) 0.64
MACE or disabling stroke 549 (30.0) 79 (47.0)  0.0001
MACE  major adverse cardiovascular events (reinfarction or ischemia-driven TVR or death); TIMI  Thrombolysis In
Myocardial Infarction; TVR  target vessel revascularization.
Figure 1. One-year adjusted survival using the Cox proportional hazards
model among patients undergoing primary percutaneous coronary inter-
vention with final TIMI 3 flow compared with those with final TIMI 3
flow. p  0.0001 for the difference in adjusted survival.
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flow. In our study, although univariate analysis revealed
several clinical and angiographic factors to be associated
with TIMI 2 flow (Tables 1 and 2), multivariate analysis
showed age 70 years, diabetes, longer time to emergency
room presentation, initial TIMI 0 or 1 flow, and LVEF 
50% to be associated independently with the increased risk
of TIMI 2 final flow. Final TIMI 2 flow is thought to
be due to microvascular dysfunction resulting from vaso-
spasm, distal embolization, endothelial dysfunction second-
ary to endothelial injury, capillary plugging by platelets,
neutrophils, and erythrocytes, and intracellular and intersti-
tial edema (28). Older age and diabetes are associated with
significant cardiovascular structural and physiologic
changes, including increase in coagulation factors (tissue
factors VII, VIII, and IX), altered neurohormonal and
autonomic influences, and endothelial and vascular smooth
muscle dysfunction, all of which may contribute to greater
vascular reactivity and tone as well as coagulation and sludge
formation in the microvasculature (29–31). The longer
delay from symptom onset to the emergency room leads to
greater myocardial necrosis, leading to more cellular edema
and microvascular injury as well as the development of larger
clot burden in the infarct-related vessel that is more likely to
cause distal embolization and sludging after primary PCI.
Initial patency of artery may suggest lower clot burden,
spontaneous lysis of the clot, favorable endogenous throm-
bolysis, resolution of vasospasm and is associated with
smaller infarct size as opposed to patients with initial TIMI
1 flow. Low LVEF is generally related to a larger infarct
size that, besides causing more microvascular damage and
interstitial edema, also decreases the coronary perfusion
pressure as a result of higher left ventricular end-diastolic
pressure. Thus, these common pathophysiologic mecha-
nisms between the development of no-reflow and STEMI
in patients with the risk variables may explain in part the
association of these variables with TIMI 2 flow.
Clinical implications. It is clear from previous studies and
our findings that TIMI 2 flow leads to poor in-hospital
and one-year outcomes. Thus, an attempt should be made
to achieve not only optimal reduction of stenosis of epicar-
dial coronary arteries but also normal microvascular flow. Of
the variables found to be associated with TIMI 2 flow in
our study, only longer time to emergency room presentation
could potentially be modified with increased public educa-
tion of the symptoms of heart attacks and the importance of
seeking immediate medical attention when they occur.
Alternatively, newer preemptive strategies that have been
shown to reduce the occurrence of final TIMI 2 flow may
be important adjuncts to primary PCI and should be used in
high-risk patients. These strategies include the use of
primary stenting (6–9,17,32), distal protection devices (33),
thrombectomy with angiojet (34), and the liberal use of
adjunctive therapies such as intracoronary adenosine, nitro-
glycerine, nitroprusside, verapamil, and nicorandil (28) or
intravenous abciximab (12,16). The role of facilitated cor-
onary angioplasty in improving final TIMI flow needs to be
proved in future studies (35). In addition, limitation of
infarct size (particularly by reducing the door-to-balloon
time), better management of stenosis, and avoidance of
Figure 2. Relationship of final TIMI flow grades after primary percutaneous coronary intervention with in-hospital and one-year mortality and major
adverse cardiovascular events (MACE). p for trend 0.0001 for all three outcomes.
Table 4. Adjusted Odds Ratios of Clinical Variables Associated
With the Risk of Final TIMI 2 Flow
Outcome
Odds
Ratio
95%
Confidence
Interval p Value
Age 70 yrs 1.57 1.11–2.20 0.01
Diabetes mellitus 1.85 1.27–2.71 0.002
Onset of chest pain to
emergency room arrival
(per every hour delay in arrival)
1.11 1.06–1.17  0.0001
Initial TIMI 1 3.24 1.91–5.51  0.0001
LVEF 50% 1.72 1.23–2.42 0.002
Model c-statistic 0.68, Hosmer-Lemeshow chi-square  11.4, degrees of freedom 8,
p  0.18.
LVEF  left ventricular ejection fraction; TIMI  Thrombolysis In Myocardial
Infarction.
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dissection may all help achieve normal flow after primary
PCI. These strategies should be employed liberally in
patients with STEMI undergoing primary PCI, particularly
those patients having risk factors for developing TIMI 2
flow as identified in our study. More research is obviously
needed to establish if this approach to patients undergoing
primary PCI will reduce the rate of post-procedural sub-
optimal coronary flow.
The underlying mechanism by which final TIMI2 flow
in patients undergoing primary PCI results in adverse
outcomes is unclear. Although a direct causal relationship
may be possible, it cannot be inferred from this study
because of the retrospective nature of our investigation.
Alternately, the clustering of final TIMI 2 flow in
high-risk groups (older age, diabetes, delay to emergency
room arrival, lower initial TIMI flow, and lower LVEF)
suggests the possibility that TIMI 2 flow may be a
surrogate marker of these high-risk patient characteristics,
explaining the poor prognosis of these patients. Future
studies are needed to address these issues.
Conclusions. Our study demonstrates that TIMI 2 flow
occurs infrequently in patients with STEMI undergoing
primary PCI and is associated with a higher incidence of
adverse events in the cardiac catheterization laboratory and
in-hospital, that persists at one year of follow-up. Further-
more, our study identified contemporary clinical and angio-
graphic factors which are strongly correlated with the risk of
TIMI 2 flow after primary PCI. Knowledge of these
factors may help clinicians identify the high-risk subgroup
that may be targeted for management strategies before and
during intervention with the intention of reducing the
occurrence of TIMI 2 flow after primary PCI and
ultimately reducing the adverse events that frequently com-
plicate this cohort.
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